Publicaciones científicas

42 Publicaciones científicas disponibles

  • Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6

    1 de octubre de 2020 | Revista: Pharmacology Research & Perspectives

    Jan de Jong  1 , Anna Mitselos  2 , Wojciech Jurczak  3 , Raul Cordoba  4   5   6 , Carlos Panizo  7   8 , Tomasz Wrobel  9 , Monika Dlugosz-Danecka  3 , James Jiao  10 , Juthamas Sukbuntherng  11 , Daniele Ouellet  12 , Peter Hellemans  2


  • RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

    20 de febrero de 2020 | Revista: Annals of Hematology

    Bastos-Oreiro M 1,2, Muntañola A 3, Panizo C 4, Gonzalez-Barca E 5, de Villambrosia SG 6, Córdoba R 7, López JLB 8, González-Sierra P 9, Terol MJ 10, Gutierrez A 11, Grande C 12, Ramirez MJ 13, Iserte L 14, Perez E 15, Navarro B 16, Gomez P 17, Salar A 18, Luzardo H 19, López A 20, Del Campo R 21, García-Belmonte D 22, Vida MJ 23, Infante M 24, Queizan-Hernandez JA 25, Novelli S 26, Moreno M 27, Penarrubia M 28, Gómez J 29, Domingo A 30, Donato E 31, Viguria MC 32, López F 33, Rodriguez MJ 34, Pardal E 35, Noriega V 36, Andreu R 37, Peñalver J 38, Martín A 39, Caballero D 39, López-Guillermo A 40.

    1 Haematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
    2 Health Research Institute, Gregorio Marañon, Madrid, Spain. 
    3 Haematology Department, Hospital Universitario Mutua Tarrasa, Tarrasa, Cataluña, Spain.
    4 Haematology Department, Clínica Universitaria de Navarra, Navarra, Spain.
    5 Haematology Department, ICO Duran y Reinalds, Bellvitlle, Cataluña, Spain.
    6 Haematology Department, Hospital of Valdesillas, Santander, Cantabria, Spain.
    7 Haematology Department, Fundación Jimenez Díaz, Madrid, Madrid, Spain.
    8 Haematology Department, University of Santiago Hospital Clinic, Santiago de Compostela, Galicia, Spain.
    9 Haematology Department, Hospital Virgen de las Nieves, Granada, Andalucía, Spain.
    10 Haematology Department, Valencia Hospital Clinic, Valencia, Spain.
    11 Haematology Department, Hospital Son Espases, Palma de Mallorca, Spain.
    12 Haematology Department, Hospital 12 de Octubre, Madrid, Spain.
    13 Haematology Department, Jerez de la Frontera Hospital, Andalucía, Spain.
    14 Haematology Department, Hospital Arnau de Vilanova, Lleida, Cataluña, Spain.
    15 Haematology department, Hospital Morales Meseguer, Murcia, Murcia, Spain.
    16 Haematology Department, University Hospital Puerta de Hierro, Mahadahonda, Madrid, Spain.
    17 Haematology Department, La Paz University Hospital, Madrid, Spain.
    18 Haematology Department, Hospital del Mar, Barcelona, Cataluña, Spain.
    19 Hospital Negrin, Las Palmas de Gran Canaria, Canary Islands, Spain.
    20 Haematology Department, Hospital Vall d' Hebron, Barcelona, Cataluña, Spain.
    21 Haematology Department, Hospital Son Llátzer, Palma de Mallorca, Spain.
    22 Haematology Department, Hospital de la Zarzuela, Madrid, Spain.
    23 Haematology Department, Hospital of León, León, Castilla y León, Spain.
    24 Haematology Department, Hospital Infanta Leonor, Madrid, Spain.
    25 Haematology Department, Hospital de Segovia, Segovia, Castilla y León, Spain.
    26 Haematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Cataluña, Spain.
    27 Haematology Department, Hospital Germans Trials y Pujol, Badalona, Cataluña, Spain.
    28 Haematology Department, Hospital Clinic of Valladolid, Castilla y León, Spain.
    29 Haematology Department, Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain.
    30 Haematology Department, Hospital de Granollers, Barcelona, Cataluña, Spain.
    31 Haematology Department, Hospital Dr. Peset, Valencia, Spain.
    32 Haematology Department, Hospital of Navarra, Navarra, Spain.
    33 Hospital Arnau de Vilanova, Valencia, Spain.
    34 Haematology Department, Hospital Universitario de Canarias SCT, Tenerife, Canary Islands, Spain.
    35 Haematology Department, Hospital Virgen del Puerto, Cáceres, Extremadura, Spain.
    36 Haematology Department, University Hospital A Coruña, A Coruña, Galicia, Spain.
    37 Haematology Department, Hospital La Fe, Valencia, Spain.
    38 Haematology Department, Hospital of Alcorcón, Alcorcón, Madrid, Spain.
    39 Haematology Department, Hospital Clinic of Salamanca, Salamanca, Castilla y León, Spain.
    40 Haematology Department, Hospital Clinic of Barcelona, Barcelona, Cataluña, Spain.


  • Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

    26 de septiembre de 2019 | Revista: Leukemia

    Wang M (1), Rule S (2), Zinzani PL (3), Goy A (4), Casasnovas O (5), Smith SD (6), Damaj G (7), Doorduijn JK (8), Lamy T (9), Morschhauser F (10), Panizo C (11), Shah B (12), Davies A (13), Eek R (14), Dupuis J (15), Jacobsen E 16, Kater AP (17), Le Gouill S (18), Oberic L (19), Robak T (20), Jain P (21), Frigault MM (22), Izumi R (22), Nguyen D (22), Patel P (22), Yin M (22), Długosz-Danecka M (2)3.

    (1) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
    (2) Plymouth University Medical School, Plymouth, UK.
    (3) Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
    (4) John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
    (5) CHU Dijon - Hôpital d'Enfants, Dijon, France.
    (6) Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
    (7) Institut d'Hématologie de Basse-Normandie, Caen, France.
    (8) Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands.
    (9) CHU de Rennes, Rennes, France.
    (10) Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000, Lille, France.
    (11) Clínica Universidad de Navarra, Pamplona, Spain.
    (1)2 Moffitt Cancer Center, Tampa, FL, USA.
    (13) Cancer Research UK Centre, University of Southampton Faculty of Medicine, Southampton, UK.
    (14) Border Medical Oncology, Albury, Victoria, Australia.
    (15) Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France.
    (16) Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (17) Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, HOVON Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands.
    (18) CHU de Nantes-Hotel Dieu, Nantes, France.
    (19) Institut Universitaire du Cancer-Oncopole Toulouse (IUCT-O), Toulouse, France.
    (20) Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
    (21) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
    (22) Acerta Pharma, South San Francisco, CA, USA.
    (23) Department of Haematology, Jagiellonian University, Krakow, Poland.


  • The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

    15 de mayo de 2019 | Revista: Clínical Cancer Research

    Moreno L (1), Perez C (1), Zabaleta A (1), Manrique I (1), Alignani D (1), Ajona D (1,2,3), Blanco L (1), Lasa M (1), Maiso P (1), Rodriguez I (1), Garate S (1), Jelinek T (1), Segura V (1), Moreno C (1), Merino J (1), Rodriguez-Otero P (1), Panizo C (1), Prosper F (1), San-Miguel JF (1), Paiva B (4).

    (1) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
    (2) Solid Tumors Program, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00443, Pamplona, Spain.
    (3) Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
    (4) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.

SOLICITE